Literature DB >> 8892899

Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

G E Hancock1, D J Speelman, K Heers, E Bortell, J Smith, C Cosco.   

Abstract

The feasibility of using the highly purified native attachment (G) protein in a subunit vaccine against respiratory syncytial virus (RSV) was examined in a murine model with or without the fusion (F) protein of RSV and the adjuvant QS-21. The studies established that QS-21 was more potent than AIOH as an adjuvant for both F and G glycoproteins. Augmented antigen-dependent killer cell activity and complement-assisted serum neutralizing and anti-F and G protein immunoglobulin G2a antibody titers were observed. Immunization with G/QS-21 generated immune responses that were characterized by low levels of antigen-dependent killer cell activity, elevated levels of interleukin-5 (IL-5) and percentages of eosinophils in the bronchoalveolar lavage fluids after challenge, and splenic immunocytes that secreted IL-5 but not gamma interferon (IFN-gamma) after in vitro stimulation with purified whole virus antigens. The pulmonary eosinophilia was similar to that induced by a facsimile of a formalin-inactivated vaccine used in previous clinical trials and was prevented by prior in vivo treatment with anti-IL-5 but not with control immunoglobulin G or anti-IFN-gamma neutralizing monoclonal antibodies. Thus the data implied that vaccination with G/QS-21 generated helper T-cell immune responses that were type 2 in nature. Alternatively, the data suggested that the helper T-cell immune responses elicited by F/QS-21 were more type 1 in character. Neither eosinophilia nor elevated levels of IL-5 were observed in the lungs of mice after challenge. Noteworthy levels of antigen-dependent killer cell activity was observed, and splenic immunocytes secreted copious quantities of IFN-gamma. Immunization with a combination vaccine composed of highly purified native F and G proteins plus QS-21 (F+G/QS-21) resulted in augmented complement-assisted serum neutralizing antibody titers compared with vaccination with either F/QS-21 or G/QS-21 alone. However, following vaccination with F+G/QS-21, the bronchoalveolar lavage fluids contained significant increases in IL-5 and percentages of eosinophils after challenge, the spleen cells appeared to secrete less IFN-gamma after in vitro stimulation, and there was no evidence of increased numbers of antigen-dependent killer cell precursors. Taken together, the data imply that native G protein influences the nature of the immune responses elicited by F/QS-21. The results therefore suggest that G, not F, protein has more potential to bias the host for atypical pulmonary inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892899      PMCID: PMC190848     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  54 in total

1.  Cytokine-induced differentiation of precursor mouse CD8+ T cells into cytotoxic CD8+ T cells secreting Th1 or Th2 cytokines.

Authors:  S Sad; R Marcotte; T R Mosmann
Journal:  Immunity       Date:  1995-03       Impact factor: 31.745

2.  Purification and characterization of GP90, one of the envelope glycoproteins of respiratory syncytial virus.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  J Gen Virol       Date:  1984-04       Impact factor: 3.891

Review 3.  Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes.

Authors:  G Trinchieri
Journal:  Blood       Date:  1994-12-15       Impact factor: 22.113

4.  Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies.

Authors:  E E Walsh; J J Schlesinger; M W Brandriss
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

5.  Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection.

Authors:  H W Kim; S L Leikin; J Arrobio; C D Brandt; R M Chanock; R H Parrott
Journal:  Pediatr Res       Date:  1976-01       Impact factor: 3.756

6.  Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10.

Authors:  M Connors; N A Giese; A B Kulkarni; C Y Firestone; H C Morse; B R Murphy
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

7.  Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus.

Authors:  E A Colocho Zelaya; C Orvell; O Strannegård
Journal:  Pediatr Allergy Immunol       Date:  1994-05       Impact factor: 6.377

8.  Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi.

Authors:  J Ma; P A Bulger; D R Davis; B Perilli-Palmer; D A Bedore; C R Kensil; E M Young; C H Hung; J R Seals; C S Pavia
Journal:  Vaccine       Date:  1994-08       Impact factor: 3.641

9.  Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial.

Authors:  R B Belshe; L P Van Voris; M A Mufson
Journal:  J Infect Dis       Date:  1982-03       Impact factor: 5.226

10.  Monoclonal antibodies protect against respiratory syncytial virus infection in mice.

Authors:  G Taylor; E J Stott; M Bew; B F Fernie; P J Cote; A P Collins; M Hughes; J Jebbett
Journal:  Immunology       Date:  1984-05       Impact factor: 7.397

View more
  60 in total

Review 1.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

2.  Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Authors:  Lia M Haynes; Les P Jones; Albert Barskey; Larry J Anderson; Ralph A Tripp
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

3.  Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.

Authors:  Naoko Iwata-Yoshikawa; Akihiko Uda; Tadaki Suzuki; Yasuko Tsunetsugu-Yokota; Yuko Sato; Shigeru Morikawa; Masato Tashiro; Tetsutaro Sata; Hideki Hasegawa; Noriyo Nagata
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

4.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Protective efficacy and immunogenicity of an adenoviral vector vaccine encoding the codon-optimized F protein of respiratory syncytial virus.

Authors:  Rebekka Kohlmann; Sarah Schwannecke; Bettina Tippler; Nicola Ternette; Vladimir V Temchura; Matthias Tenbusch; Klaus Uberla; Thomas Grunwald
Journal:  J Virol       Date:  2009-09-23       Impact factor: 5.103

6.  Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.

Authors:  Monali M Bera; Bao Lu; Thomas R Martin; Shun Cui; Lawrence M Rhein; Craig Gerard; Norma P Gerard
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

7.  Gamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragment.

Authors:  Helene Plotnicky-Gilquin; Dominique Cyblat-Chanal; Jean-Pierre Aubry; Thierry Champion; Alain Beck; Thien Nguyen; Jean-Yves Bonnefoy; Nathalie Corvaïa
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus.

Authors:  L M Haynes; D D Moore; E A Kurt-Jones; R W Finberg; L J Anderson; R A Tripp
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

9.  Cross-resistance mechanism of respiratory syncytial virus against structurally diverse entry inhibitors.

Authors:  Dan Yan; Sujin Lee; Vidhi D Thakkar; Ming Luo; Martin L Moore; Richard Karl Plemper
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-04       Impact factor: 11.205

10.  Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.

Authors:  Luis Enjuanes; Marta L Dediego; Enrique Alvarez; Damon Deming; Tim Sheahan; Ralph Baric
Journal:  Virus Res       Date:  2007-04-09       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.